OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products Mar 28, 2018 12:07PM
OSE Immunotherapeutics: 2017 Annual Results and Clinical Advances of its Proprietary and Partnered Products Mar 28, 2018 12:00PM
OSE Immunotherapeutics Announces Participation At The H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 Mar 27, 2018 12:00PM
OSE Immunotherapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 Mar 27, 2018 12:00PM
OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor T Mar 15, 2018 01:00PM
View Older Stories

Mar 15, 2018 01:00PM OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor T
Feb 28, 2018 12:00PM OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®
Feb 28, 2018 12:00PM OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®
Feb 27, 2018 01:30AM OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Tre
Feb 27, 2018 01:30AM OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Tre
Jan 25, 2018 12:00PM OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Appli
Jan 25, 2018 12:00PM OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Appli
Jan 4, 2018 02:00AM OSE Immunotherapeutics to present at Biotech Showcase™ 2018 Conference
Jan 4, 2018 02:00AM OSE Immunotherapeutics to Present at Biotech Showcase™ 2018 Conference
Jan 3, 2018 02:00PM OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors
Jan 3, 2018 02:00PM OSE Immunotherapeutics Announces Appointment of Gérard Tardy as Chairman of Company’s Board of Directors
Dec 19, 2017 02:00AM OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
Dec 19, 2017 02:00AM OSE Immunotherapeutics Presents New Data Analysis Supporting Continued Development of OSE-127 in Inflammatory Bowel Diseases
Dec 14, 2017 12:00PM OSE Immunotherapeutics Receives a Grant From French Government Program “Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies
Dec 14, 2017 12:00PM OSE Immunotherapeutics Receives a Grant from French Government Program “Fonds Unique Interministériel” to Explore New Cytotoxic Antibodies
Dec 7, 2017 01:30AM OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
Dec 7, 2017 01:30AM OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
Oct 26, 2017 12:00PM OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE®
Oct 26, 2017 12:00PM OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE®
Oct 19, 2017 12:00PM OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
Oct 19, 2017 12:00PM OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
Oct 2, 2017 12:00PM OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment
Oct 2, 2017 12:00PM OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment
Sep 28, 2017 12:00PM OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
Sep 28, 2017 12:00PM OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells
Sep 26, 2017 08:00AM Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
Sep 26, 2017 02:00AM Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
Sep 26, 2017 02:00AM Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
Sep 7, 2017 12:00PM OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio
Sep 6, 2017 01:30AM OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer
Aug 31, 2017 12:00PM OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference In New York City, September 10-12, 2017
Aug 31, 2017 12:00PM OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017
Jul 19, 2017 12:00PM OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)
Jul 19, 2017 12:00PM OSE Immunotherapeutics Receives €9.2 Million Grant From Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)
Jun 23, 2017 03:00PM OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer
Jun 23, 2017 03:00PM OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer
Jun 21, 2017 12:30PM OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
Jun 21, 2017 12:30PM OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
Jun 15, 2017 12:00PM OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clin
Jun 15, 2017 12:00PM OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases
Jun 14, 2017 01:00PM OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders
Jun 14, 2017 12:00PM OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders
May 23, 2017 11:45AM Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE's Interleukin Receptor 7 Antagonist
May 23, 2017 11:45AM Selexis SA And OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist
May 22, 2017 12:00PM OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists
May 18, 2017 12:00PM OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
May 18, 2017 12:00PM OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
May 15, 2017 12:15PM OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress,” London, May 1
May 15, 2017 12:15PM OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress”, London, May 1
Apr 5, 2017 02:00AM OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Me
View Older Stories